SITE010-0095

SITE010 (ESP) › SITE010-0095

SITE010-0095

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2025-12-30

completed

AEs

3

Serious

1

Dropout signal

–

Adverse events

3

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-09-30 (study day 91); relationship: not assessed

mild assessed

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-03 (study day 64); relationship: NOT RELATED; serious criteria: life-threatening

severe serious assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-07-19 (study day 18); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.